Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis

NCT05655299 is registered in ClinicalTrials.gov with Ventyx Biosciences, Inc as lead sponsor.

NCT NCT05655299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05655299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis
Lead sponsor
Ventyx Biosciences, Inc
Phase
Phase 2
Overall status
Terminated
Start date
November 17, 2022
Completion date
December 20, 2023
Enrollment
222 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis